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a b s t r a c t
The rapidly evolving ﬁeld ofmolecular imaging promises important advances in the diagnosis, character-
ization and pharmacological treatment of vascular disease. Magnetic resonance imaging (MRI) provides
a modality that is well suited to vascular imaging as it can provide anatomical, structural and functional
data on the arterialwall. Its capabilities are further enhancedby theuse of a rangeof increasingly sophisti-
cated contrast agents that target speciﬁcmolecules, cells and biological processes. This articlewill discuss
one such approach, using microparticles of iron oxide (MPIO).
MPIO have been shown to create highly conspicuous contrast effects on T2*-weighted MR images.
We have developed a range of novel ligand-conjugated MPIO for molecular MRI of endothelial adhesion
molecules, such as vascular cell adhesion molecule-1 (VCAM-1) and P-selectin expressed in vascularicroparticles of iron oxide
therosclerosis
hrombosis
ascular inﬂammation
schemia-reperfusion injury
inﬂammation, as well as activated platelet thrombosis. This review discusses the application of ligand-
targeted MPIO for in vivo molecular MRI in a diverse range of vascular disease models including acute
vascular inﬂammation, atherosclerosis, thrombosis, ischemia-reperfusion injury and ischemic stroke. The
exceptionally conspicuous contrast effects of ligand-conjugated MPIO provide a versatile and sensitive
tool for quantitative vascular molecular imaging that could reﬁne diagnosis and measure response to
treatment. The potential for clinical translation of this new class of molecular contrast agent for clinical
imaging of vascular syndromes is discussed.
© 2009 Elsevier Ireland Ltd. 
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. Introduction
In clinical practice, the early identiﬁcation and characteriza-
ion of atherosclerotic lesions at risk of progressing to cause
yocardial infarction (MI) and ischemic stroke remains challeng-
ng. X-ray arteriography is the standard clinical imaging technique
sed to estimate the degree of luminal stenosis, but detects only
he silhouette of the vessel wall against the lumen and does
ot provide information on plaque composition. More sophis-
icated non-invasive imaging techniques are required that can
ccelerate and reﬁne diagnosis, guide intervention and monitor
esponse to therapies that may stabilize lesions and prevent future
therothrombotic events [1].
Molecular imaging is a rapidly evolving ﬁeld, which presents
pportunities to shift emphasis from imaging plaque structure to
eporting directly the biological processes of vascular disease at the
olecular and cellular levels [2]. Speciﬁc targeting of molecules
s achieved through the development of purpose-built molecular
magingprobes, usually consisting of a contrast agent conjugated to
peciﬁc targeting ligands [1]. Advances in nanotechnology have led
o the development of an array of nano- andmicrometer-sized par-
icle contrast agents for application inmolecular imaging. Themost
uccessful approacheshave involved thedevelopment ofmolecular
maging agents that can deliver substantial payloads of paramag-
etic gadolinium (Gd) chelates or superparamagnetic iron oxide to
speciﬁc molecular target (Fig. 1). Functionalization of the particle
urface with reactive surface groups enables covalent conjugation
f a variety of targeting ligands including antibodies, peptides,
ptamers and small molecule peptidomimetics to the particle sur-
ace.
In atherosclerosis, a diverse range of molecular targets are
xpressed both at the endothelial surface and by cells within
he vessel wall of the artery. Importantly, there is differential
xpression of some of these targets from early lesion formation to
dvancedvulnerable plaques and thrombotic complications [1,3,4].
or instance, earlymarkersof atherogenesis includeendothelial cell
dhesion molecules, such as P- and E-selectin, vascular cell adhe-
ion molecule-1 (VCAM-1) and intercellular adhesion molecule-1
ICAM-1), which facilitate mononuclear leukocyte recruitment to
ctivated endothelium and subsequent transmigration into the
ubendothelial space [5–7].Molecular imagingof endothelial adhe-
ion molecules has been at the forefront of this ﬁeld, since the
pregulation of thesemolecules is an early event in a broad range of
ascular diseases including atherosclerosis, ischemia-reperfusion
njury, ischemic stroke and cancer. Furthermore, their endothe-
ial locationmakes them accessible to blood-borne contrast agents.
owever, one of the challenges for molecular imaging of endovas-
ular targets is to deliver targeted contrast agents in sufﬁcient
ensity todetectmolecular expressionof relatively low-abundance
ig. 1. MRI relies on the delivery of relatively high payloads of either (A) gadolinium chel
d requires interaction with local water molecules to produce contrast effects. Iron oxi
hells. USPIO: ultrasmall particles of iron oxide; CLIO: cross-linked iron oxide nanoparticrosis 209 (2010) 18–27 19
targets conﬁned to a two-dimensional endothelial monolayer and
to achieve this under high physiological shear stresses.
Shapiro et al. showed that microparticles of iron oxide (MPIO)
provide excellent contrast effects [8]. In this paper, we will
focus on the application of ligand-targeted MPIO for molecular
MRI of endothelial adhesion molecules in experimental models
of acute vascular inﬂammation [9], ischemia-reperfusion injury
[10], atherosclerosis [11] and ischemic stroke [12]. We also high-
light a similar ligand-targeted MPIO strategy for MRI detection
of activated platelet thrombosis. Finally, we discuss the scope for
application of ligand-targeted MPIO in clinical imaging of vascular
syndromes.
2. Molecular imaging modalities
A range of imaging techniques are currently used to
image atherosclerosis including intravascular ultrasound (IVUS),
multiple-row detector computed tomography (MDCT), positron
emission tomography (PET), MRI and optimal coherence tomog-
raphy (OCT) [13]. Of these only nuclear techniques have proven
record in clinical molecular imaging. PET can assess atheroscle-
rotic inﬂammatoryplaqueactivityusing exogenously administered
18Fluorine preparations, such as 2-[18F]ﬂuoro-2-deoxy-d-glucose
(FDG). This glucose analogue accumulates in metabolically active
tissue, yielding a signal that is proportional to glycolytic activ-
ity. It has been shown that inﬂamed, metabolically active, plaques
may be detectable by 18FDG-PET. Rudd et al. demonstrated the
ability of 18FDG-PET imaging to highlight inﬂammatory activ-
ity in unstable carotid plaques in patients undergoing carotid
endarterectomy, relative to the contralateral asymptomatic artery
[14]. 18FDG was taken up by atherosclerotic plaque and selec-
tively accumulated in macrophage-rich areas. Indeed, the ﬁrst
investigations of treatment effects of on plaque activity are begin-
ning to emerge [15]. The advantages of PET are related to its
extreme sensitivity and quantitative outputs. Opportunities to
apply PET in the evaluation of atherosclerosis and its treat-
ment should extend beyond macrophage imaging through the
development of novel ‘radio-ligands’. For example, the develop-
ment of imaging probes that target matrix metalloproteinases
[16], serine proteases [17] and apoptosis [18–20], could allow
the visualization of response to treatment in ‘high risk’ plaques.
While PET hasmuch higher detection sensitivity (picomolar range)
than MRI, and much better tissue penetration than ultrasound or
OCT, the disadvantages of PET are its limited spatial resolution,ates or (B) iron oxide. Gd chelates decorate the surface of the carriage vehicle since
de particles (size range, ∼10nm to 5m) are typically contained within polymer
les; MPIO: microparticles of iron oxide[4].
expense.
MRI has emerged as a leading non-invasive imaging modality
for assessing vascular pathologies, due to its excellent spatial res-
olution (sub-millimeter) and soft tissue contrast and high signal
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o noise ratio. Using multi-contrast sequences, MRI can differen-
iate atherosclerotic plaque composition, based on differences in
iophysical and biochemical properties such as chemical compo-
ition and concentration, water content, physical state, molecular
otion or diffusion [1]. High resolution MRI can also accurately
uantify plaque components such as ﬁbrous cap thickness and
ize of the lipid core [21,22]. Since MRI does not involve ioniz-
ng radiation, serial imaging can be performed safely over time
ithin the same patient. Furthermore, intravenous Gd-based or
ron oxide-basedMRI contrast agents can beused to improve image
ensitivity to enhance differences between healthy and diseased
essels.
. Gadolinium based contrast agents
Gd chelates, such as gadolinium diethylene-triamine-penta-
cetic acid (Gd-DTPA), provide positive signal enhancement on T1
eighted MR images due to their effects on shortening water pro-
on T1 relaxation times. However, Gd chelates have inherently low
ensitivity (micromolar range). Formolecular imaging, a number of
trategies have been employed to amplify the Gd contrast effects
nd to deliver sufﬁcient quantities of Gd in vivo in order to detect
iological activity of lesions. A range of nanoparticles carrying sub-
tantial payloads of amphipathic Gd chelates embedded in their
uter membrane have been constructed, including liposomes [23],
erﬂuorocarbon lipid emulsions [24] andmicelles [25,26]. Lipopro-
einmicelles enrichedwithhydrophobicGdchelateshavealsobeen
eveloped for the detection of macrophages within atheroscle-
otic plaques [27–29]. However, the relaxivity effects achievable
re relatively modest, compared to superparamagnetic particles
f iron oxide (SPIO) [27,30]. A further potential disadvantage of
ydrophobic Gd chelates is the recently observed severe long-
erm toxicity effects (including nephrogenic sclerosing ﬁbrosis:
SF) in patients with impaired renal function [31]. However, it
ay be the case that targeted contrast agents could be used at
ower total Gd-dose, reducing the potential for this type of toxi-
ity.
. Nano- and micrometer-sized particles of iron oxide
Superparamagnetic iron oxide-based agents consist of a core of
ron oxides, surrounded by a dextran or polymer coat. Iron oxide
gents, shorten T2 and T2* relaxation times, creating hypointense
reas that appear black on the MR image on T2- and T2*-weighted
R images. Iron oxide agents include ultrasmall superparam-
gnetic particles of iron oxide (USPIO) (20–50nm diameter),
uperparamagnetic particles of iron oxide (SPIO) (60 to approx-
mately 250nm) and micrometer-sized particles of iron oxide
MPIO) (0.9–8m). Iron oxide agents have superior sensitivity in
R contrast, compared to Gd [32,33]. In particular, MPIO convey
payload of iron oxide (typically 0.1–1.6pg iron/MPIO parti-
le), which is orders of magnitude greater than that contained in
anometer-sized particles [8]. The effects of MPIO on local mag-
etic ﬁeld homogeneity and detectable contrast extend a distance
p to 50 times the physical diameter of the microparticle, known
s a contrast “blooming effect” [34]. MPIO have been shown to be
seful for cellularMRI, enabling in vivo detection of single cells [35]
nd cell tracking [8] using only a small number of MPIO.
For molecular imaging of endovascular targets, MPIO offer a
umber of important attributes. First, the relatively large size
nd incompressible nature of MPIO, makes them less suscepti-
le to non-speciﬁc vascular egress or uptake by endothelial cells
han nanometer-sized particles [36], thus they can retain speci-
city for endothelial molecular targets. Secondly, unbound MPIO
ave been shown to clear rapidly from the blood (blood half-liferosis 209 (2010) 18–27
<2min in rats), thus minimising background blood phase contrast
[37]. Conversely, USPIO have a long blood half-life (up to 24h),
which for MRI of endothelial molecular targets, may cause high
background contrast for an extended period, making it difﬁcult to
distinguish speciﬁc contrast effects fromnormal tissueheterogene-
ity and other susceptibility artefacts. However, “positive” contrast
MRI sequences are beingdeveloped to generateMRsignal enhance-
ment from regions containing iron oxide particles [38,39]. Thirdly,
due to the contrast “blooming effect” of MPIO, a small number
of MPIO can create potent hypointense contrast effects on T2*-
weighted images, thereby greatly enhancing sensitivity, especially
for low-abundance endothelial molecular targets. MPIO contrast
effects may be readily distinguished on T2*-weighted images using
in vivo gradient-echo MRI. MPIO have been demonstrated to pro-
vide a platform for quantitative molecular imaging of vascular
endothelial targets, whereby the extent of contrast effects may
directly report speciﬁc molecular endothelial expression [9–11].
Recently, SPIO with optimised high relaxation properties
have been developed for quantitative in vivo MRI of lipoprotein
metabolism [40] and ultra-sensitive detection of bacteria [41]. Cor-
mode et al. have demonstrated that iron oxide nanocrystals can be
used instead of Gd to label high density lipoprotein (HDL) particles
formolecular imaging ofmacrophage expression in atherosclerosis
[42].Whilst effective for the applications reported, the small size of
these particles is likely to be limiting to their application in molec-
ular endothelial imaging, where the delivery of sufﬁcient contrast
volume is challenging, on the ‘planar’ target that is on the surface
of the blood vessel wall.
5. Targeted micrometer-sized particles of iron oxide
The targeting of MPIO to speciﬁc molecules may be accom-
plished by the conjugation of ligands to functional groups on the
surface of themicroparticle. MPIO are commercially available with
a variety of reactive surface groups including carboxylic acid, amine
andp-toluene sulphydryl (tosyl) groups. These functionalizedMPIO
offer opportunities to covalently conjugate a range of targeting
ligands including monoclonal antibodies or their immunospeciﬁc
fragments F(ab), aptamers or small peptides generated by phage
display or small molecule screens. Phage display provides a pow-
erful method for the production of novel antibody or peptide
ligands from libraries of bacteriophage (viruses that infect bacterial
cells) using standard recombinant DNA technology. Functionalized
MPIO therefore provide a versatile platform that can be readily
adapted for molecular imaging of a variety of endovascular molec-
ular targets in experimental, pre-clinical investigations of vascular
inﬂammatory diseases. In Table 1, applications of targeted and
non-targeted MPIO for molecular and cellular imaging of vascular
syndromes are listed.
We have applied tosyl-activated MPIO for direct covalent
conjugation of monoclonal antibodies directed against vascular
endothelial adhesion molecules, including P-selectin and VCAM-1,
which are involved in leukocyte recruitment during early vascular
inﬂammation. Below, we review the application of tosyl-activated
MPIO for in vivo molecular MRI detection of vascular endothe-
lial adhesion molecule upregulation in diverse models of clinically
important vascular pathologies including acute vascular inﬂam-
mation [9], atherosclerosis [11], ischemia-reperfusion injury [10]
and ischemic stroke [12].We also highlight the application of simi-
lar cobalt-functionalized MPIO for direct covalent conjugation to
histidine (His) tagged single-chain antibodies, targeted towards
activated platelets in mouse models of atherothrombosis [43,44].
Finally, we discuss the potential clinical translation of ligand-
targeted MPIO as a versatile adjunct in the clinical imaging arena.
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Table 1
Approaches to molecular and cellular imaging of vascular syndromes using microparticles of iron oxide.
Biological process Target MPIO agent MR ﬁeld strength (T) Disease model
Targeted
Inﬂammation VCAM-1 VCAM-MPIO (1m) 7T in vivo Acute inﬂammation [9]
7 T in vivo EAE [88,89]
9.4 T in vivo IRI [10]
7T in vivo Experimental stroke [12]
P-selectin +VCAM-1 P/V-MPIO (4.5m) 11.7 T ex vivo Atherosclerosis [11]
Activated platelets GP IIb/IIIa LIBS-MPIO (1m) 9.4 T ex vivo Atherothrombosis [37]
7T in vivo Infection [90]
1.5 and 3T ex vivo Human platelets [38]
9.4 T in vivo Thrombosis [38]
Untargeted
Macrophage tracking Macrophages MPIO (0.9m) 4.7 T in vivo Cardiac allograft rejection [36]
4.7 T in vivo Heart transplant rejection [91]
Stem cell migration Stem cells 1.5 T in vivo Myocardial infarction [92]
MPIO: microparticles of iron oxide; VCAM-1: vascular cell adhesion molecule-1; IRI: ischemia-reperfusion injury; EAE: experimental allergic encephalomyelitis; LIBS:
ligand-induced binding sites; P/V-MPIO: P-selectin and VCAM-1 antibody-conjugated MPIO.
Fig. 2. Imaging of VCAM-1 in acute inﬂammation. (A) Confocal microscopy of TNF- stimulated sEND-1 cells. Green ﬂuorescence reﬂects VCAM-1 expression on the cell
surface. Prior incubation of VCAM-MPIO with Fc-ICAM-1 had no effect on VCAM-MPIO binding (autoﬂuorescent green spheres), whereas pre-incubation with Fc-VCAM-1
abolished VCAM-MPIO retention, despite demonstrable VCAM-1 surface expression. Graph depicts retained VCAM-MPIO (mean± S.D.) with andwithout pre-incubationwith
soluble Fc-VCAM-1 or Fc-ICAM-1 (*P<0.0001). (B) In vivo T2*-weighted MR coronal images (4 images per brain; resolution ∼90m3). Intense low signal areas (highlighted
with red box) on the left side of the brain reﬂect speciﬁc MPIO retention (VCAM-MPIO (row 1) VCAM+P-selectin MPIO (row 2)) on acutely activated vascular endothelium
with almost absent contrast effect in the contralateral hemisphere (green box). No contrast effects were observed with IgG-MPIO control (row 3) or pre-treatment with
VCAM-1 antibody prior to VCAM-MPIO administration, which effectively blocked VCAM-MPIO binding (row 4). Scale bar, 5mm. (C) Three-dimensional volumetric maps of
VCAM-MPIO contrast effects (red) delineate the architecture of cerebral vasculature in the IL-1-stimulated hemisphere (left half of top image) with almost total absence
of binding on the contralateral, non-activated side. The midlines are indicated by vertical sections. Pre-administration of VCAM-1 antibody abolished VCAM-MPIO retention
(lower image). Quantitative analyses ofMPIO contrast effects found that speciﬁcVCAM-MPIO contrastwas increased >100-fold, comparedwith brainswithout IL-1 injection.
Dual-targetedVCAM+P-selectinMPIO also bound speciﬁcally but did not further enhance contrast effects. Substitution of IgG-MPIO (IgG/IL-1+), sham intracerebral injection
(VCAM/NaCl), no intracerebral injection (VCAM/IL-1−) and pre-blocking (VCAM/IL-1+ with block) were not associated with speciﬁc contrast effects. Bars indicate mean
values for each group (*P=0.02) [9].
22 M.A. McAteer et al. / Atherosclerosis 209 (2010) 18–27
Fig. 3. Dual-targetedMPIO binding inmouse atherosclerosis. (A) Dual-ligandMPIO recognizing VCAM-1 and P-selectin showed 7-fold enhanced binding to aortic root plaque
endothelium compared to single-ligand MPIO targeting either VCAM-1 or P-selectin, following left ventricular injection. **P<0.01; *P<0.05. (B) Dense dual-targeted MPIO
binding to endothelium overlying atherosclerotic plaque. Scale bar, 20m. (C) Ex vivo MRI of aortic roots 30min after i.v. injection of MPIO. Dual-targeted MPIO binding
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gG-MPIO. Scale bar, 500m. (D) 3D reconstruction of dual-targeted MPIO contrast
. Molecular imaging of acute vascular inﬂammation
Acute inﬂammation of the central nervous system (CNS) is
ssociated with enhanced expression of endothelial adhesion
olecules. Endothelial VCAM-1 and its ligand, 41 integrin (also
alled very late antigen-4, VLA-4) are key mediators of leukocyte
ecruitment and lesion development [45]. VCAM-1 is not constitu-
ively expressed on the vascular endothelium but is up-regulated
pon endothelial activation [46]. Furthermore, selective VCAM-1
nhibitors such as natalizumab that bind to the 4 subunit of
41 integrin are effective anti-inﬂammatory agents, for instance
n the treatment of multiple sclerosis [47]. For these reasons,
CAM-1 is an attractivemolecular imaging target of acute vascular
nﬂammation.
VCAM-1 targeted MPIO can conspicuously show upregulation
f VCAM-1 in a mouse model of early cerebral inﬂammation
y molecular in vivo MRI, at a time when pathology is oth-
rwise undetectable by conventional imaging techniques [9].
PIO (1m diameter), with reactive tosyl groups, were cova-
ently conjugated tomousemonoclonal antibodies against VCAM-1
VCAM-MPIO) or IgG isotype negative control. The capacity of
CAM-MPIO constructs for speciﬁc and quantitative binding
as tested in vitro using a mouse endothelial cell line (sEND-
), stimulated with graded doses of tumor necrosis factor-
TNF-). Differential interference confocal microscopy showed a
NF- dose-dependent increase in VCAM-MPIO binding, which
o-localized with VCAM-1 immunoﬂuorescence on the endothe-
ial cell surface. Furthermore, VCAM-MPIO binding to stimulated
ells was inhibited when the VCAM-MPIO were pre-incubatedosclerotic plaque. Minimal contrast effects were observed with negative isotype
s through the aortic root [21].
with soluble decoy VCAM-1 (mouse recombinant Fc-VCAM-1)
(Fig. 2A).
For in vivo experiments, pro-inﬂammatory interleukin 1 (IL-
1) was stereotactically injected into the left corpus striatum of
NMRI mice to induce acute vascular inﬂammation. The contralat-
eral hemisphere received no injection and served as an internal
control. VCAM-MPIO or negative control IgG-MPIO (∼4.5mg/kg
body weight) were intravenously injected 3h after IL-1 injec-
tion and allowed to circulate for 1.5–2h prior to MRI. To block
VCAM-1 binding sites, a further group of mice were pre-treated
with VCAM-1 antibody 3h after IL-1 injection and VCAM-MPIO
administered 15min later. In vivo MRI was performed at 7T
using a T2*-weighted 3D gradient-echo sequence (acquisition
∼1h; isotropic resolution 88m3). VCAM-MPIO produced highly
speciﬁc hypointense signal areas in the IL-1 activated hemi-
sphere, which delineated the architecture of activated cerebral
blood vessels, with minimal contrast effects in the contralat-
eral, unstimulated hemisphere (Fig. 2B and C). Mice that received
negative control IgG-MPIO and mice pre-treated with VCAM-1
antibody prior to VCAM-MPIO injection also showedminimal con-
trast effects. The speciﬁcity and potency of VCAM-MPIO contrast
effects were derived from a combination of targeted delivery of
MPIO containing a large amount of iron oxide to sites of early
inﬂammation and rapid clearance of MPIO from the blood which
minimizes background signal. Previously, Gd-based nanoparticles
conjugated to Sialyl Lewisx (sLeX) mimetic moiety (Gd-DTPA-
sLexA) have been reported to detect early endothelial activation
of E-selectin in a rat model of brain inﬂammation [48]. Detec-
tion of ICAM-1 upregulation has also been reported by ex vivo
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Fig. 4. MRI of activated platelets using MPIO conjugated to single-chain antibodies directed against ligand-induced binding sites (LIBS). (A) (i) Ex vivo MRI of a wire-injured
femoral artery exposed to LIBS-MPIO shows multiple, intensely low signal, lobulated areas at the interface between vessel wall and lumen (arrows). (ii) Three-dimensional
reconstruction shows diffuse and relatively even LIBS-MPIO binding along the luminal surface of the injured femoral artery. (iii) Co-localization of LIBS-MPIO andplateletswas
conﬁrmed using immunohistochemistry for CD62 [43]. (B) Confocal microscopy of human platelets immobilized on ﬁbrinogen and detected by immunoﬂuorescence using
CD62 antibody (green) [43]. (i) LIBS-MPIO (red) show speciﬁc binding to platelets. (ii) No binding was observed with control-MPIO. (iii) 3D rendering shows multiple LIBS-
MPIO binding to clusters of activated platelets, via GPIIb/IIIa. (C) In vivo T2*-weighted MRI after carotid artery injury [44]. Transverse sections demonstrate the injured right
carotid artery (red circle), and the non-injured left carotid artery (green circle). Following LIBS-MPIO injection, there is increasing signal drop at 12, 24, and 72min compared
with preinjection and the non-injured left carotid artery. For control-MPIO, signal intensity is similar at 12, 48, and 72min in both vessels. (D) Immunohistochemistry of
w t boun
o bindi
r [44].
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ball-adherent thrombus in a LIBS-MPIO-injected animal. In the inset, arrows depic
f MPIO bound to wall-adherent thrombosis shows signiﬁcantly higher LIBS-MPIO
ecombinant urokinase to induce thrombolysis, prior to LIBS-MPIO administration
RI (9.4 T) using antibody-conjugated paramagnetic liposomes
49].
. Molecular imaging of atherosclerosis using
ual-targeted MPIO
In the application described above, MPIO accumulate in cere-
ral venules, where shear stresses and ﬂow rates are relatively
ow. Atherosclerosis, however, is characterized by the accumula-
ion of lipid-rich, ﬁbrous and cellular elements within the wall
f large and medium-sized arteries, including the coronary and
arotid arteries, as well as the aorta and peripheral vessels [50–52].
olecular imaging of the vascular endothelium of large arter-
es presents challenges since the contrast agent has to bind in
ufﬁcient density to a two-dimensional monolayer exposed to
igh physiological shear stress conditions. The dynamics of leuko-
yte binding to activated endothelium are complex and rely on
ultiple receptor-ligand interactions. Initial leukocyte rolling is
ediated by E- and P-selectin whereas ﬁrm adhesion to the
ascular wall is mediated via integrin binding with intercellu-
ar adhesion molecule-1 (ICAM-1) and VCAM-1, with the latter
ore important in initiation of atherosclerosis [6,53]. VCAM-1 is
ot constitutively expressed but is upregulated at atherosclerosis-
rone sites even before macroscopic disease is apparent, with
ersistent expression in more advanced atherosclerotic lesions
54,55]. Computed models of adhesion molecule dynamics pre-
ict synergistic roles for selectins and integrins with transition
etween rolling andﬁrmadhesiondependent on the binding afﬁni-d MPIO on the thrombus surface (thrombus area itself appears red). Quantiﬁcation
ng compared to control-MPIO or to mice treated with human urokinase or mouse
ties and relative concentrations of receptor-ligand interactions
[56,57].
In order to mimic the in vivo multi-step dynamics of leukocyte
adhesion, we have constructed dual antibody-conjugated MPIO
(4.5m diameter) using monoclonal antibodies to P-selectin and
VCAM-1, in a 50:50 combination (PV-MPIO) [11]. As predicted by
computed models, we have demonstrated using in vivo bioassays
that dual-targeted MPIO markedly enhance binding to atheroscle-
rotic plaque endothelium compared to single-ligand MPIO (7-fold
increase in binding compared with P-selectin-MPIO and 6-fold
increase compared with VCAM-MPIO) (Fig. 3A) [11]. The ability
of dual-ligand PV-MPIO to bind to aortic root plaque endothelium
in vivo was then investigated using apo E−/− mice, fed a high fat
diet for 26 weeks. Apo E−/− mice were intravenously injected with
dual-targeted PV-MPIO or negative control IgG-MPIO (30mg iron
per kg bodyweight) and allowed to circulate for 30min. Mice were
terminally anesthetized and the arterial tree perfusion ﬁxed and
embedded in an MR tube for high resolution ex vivo MRI (9.4 T).
MPIO binding was readily distinguished on the arterial endothe-
lium of plaque, providing excellent visualization by MRI (Fig. 3C).
3D reconstruction of segmented images demonstrated speciﬁc
PV-MPIO binding localized to atherosclerotic plaque endothelium
throughout the aortic root, with minimal retention of IgG-MPIO
(Fig. 3D). No MPIO binding was observed in atherosclerosis-free
areas of the ascending aorta.
We had purposely used relatively large MPIO (4.5m diame-
ter) to target endothelial adhesion molecule expression in aortic
atherosclerotic plaques because of their presumed superior con-
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Fig. 5. (A) Histological section depicting the considerably smaller size of MPIO (1m diameter) (black arrow) bound to endothelium overlying aortic root plaque, compared
to adjacent red blood cells (red arrows). (B) In vivo biodistribution studies show that MPIO retention by the lungs is minimal, while MPIO uptake by the spleen and liver is
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sapid [43]. (C) Schematic representation of the biological handling properties of biod
ndothelial system is advantageous for in vivo imaging, where background blood M
he dextran coat and iron via normal iron handling pathways is required.
rast effects [8]. However, the dual-ligand conjugation protocol
ould be applied to smaller 1m diameter MPIO, which we now
ppreciate may be less buoyant in the circulation that these larger
PIO and thereforemay exhibit effective contrast binding at lower
oses. Similar dual-targeted microbubbles conjugated with Sialyl
ewisx and ICAM-1 antibody have also been developed for molec-
lar ultrasound imaging, although in that case, binding efﬁciency
as increased only marginally by the combination. We speculate
hat this was due to stearic limitations resulting from the size mis-
atch of the glycoprotein and antibody ligands [58]. Several iron
xide nanoparticle agents conjugated to novel VCAM-1 internalis-
ng peptides, identiﬁed by phage display have also been reported.
hese peptides bind speciﬁcally to activated endothelium and are
nternalized by cells expressingVCAM-1, allowing progressive con-
entration by endothelial cells [59,60].
. Molecular imaging of ischemia-reperfusion injury
Vascular inﬂammation is a key feature following ischemia-
eperfusion injury (IRI) [61] in acute vascular syndromes such
s myocardial infarction [62–64], stroke [65,66], cardiac surgery
67] and organ transplantation [68]. The upregulation of endothe-
ial adhesion molecule expression persists after the ischemic
vent itself has resolved and therefore may provide a functional
mprint of a prior ischemic insult [69]. We have recently shown
hat VCAM-MPIO (1m diameter) can detect VCAM-1 expres-
ion in a mouse model of unilateral renal IRI [10,70]. We alsoable MPIO. Efﬁcient removal of contrast agent from the circulation via the reticulo-
ay otherwise obscure speciﬁcally bound contrast. Disintegration and dispersal of
identiﬁed in vitro using TNF- stimulated cells that VCAM-MPIO
binding correlates with both VCAM-1 protein and mRNA levels,
as determined by western blotting and RT-PCR respectively [10].
For in vivo studies, IRI was induced in male C57BL/6 mice by
clamping the left renal pedicle for 30min, while the contralat-
eral pedicle was exposed but not instrumented [71]. After 16–18h
reperfusion, mice were intravenously injected with VCAM-MPIO
or irrelevant control IgG-MPIO (4.5mg iron per kg). A further
group of mice were pre-treated with VCAM-1 antibody 15min
prior to VCAM-MPIO injection to block VCAM-1 binding sites. In
vivo MRI (9.4 T) was performed for 90min post-contrast injection
using a double-gated 3D gradient-echo sequence, optimized to
provide both bright blood and T2*-weighted contrast (resolution
100m3). Signiﬁcant VCAM-MPIO binding was observed in both
the medulla and cortex of IRI kidneys compared with irrelevant
control IgG-MPIO. Pre-treatment of mice with VCAM-1 antibody
prior to VCAM-MPIO administration abolished retention of VCAM-
MPIO.
Recently, Hoyte et al. have demonstrated that VCAM-MPIO can
detect unilateral cerebral ischemia in a mouse model of experi-
mental stroke [12]. Barber et al. have also reported molecular MRI
of transient middle cerebral artery brain ischemia using Gd-DTPA-
sLexA, targeting both P- and E-selectin, but identiﬁed limitations in
contrast sensitivity [72]. Targeted ultrasound microbubbles, tar-
geting P-selectin and ICAM-1 have been developed and applied
to image mouse renal [73,74] and myocardial IRI [75,76]. Cur-
rent clinical imaging techniques are hampered by an inability to
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eﬁne the extent anddistributionof ischemia in acute vascular syn-
romes. The ability of our ligand-targetedMPIO approach to depict
he volume of endothelial inﬂammation following IRI, in relation
o the vasculature, may aid accelerated diagnosis of parenchymal
schemia and potentially, guide targeted interventions.
. Molecular imaging of thrombus using MPIO targeted to
ctivated platelets
Activated platelets are known to be involved both in the initia-
ion of atherosclerosis and in advanced atherosclerotic events, such
s plaque rupture and thrombus formation [77,78,79]. The platelet-
peciﬁc glycoprotein GP IIb/IIIa receptor (CD41/CD61, also known
s IIb3 integrin) mediates the ﬁnal common pathway of platelet
ggregation via ﬁbrinogen and is key to thrombus formation
80]. Recently, a single-chain antibody that speciﬁcally recog-
izes ligand-induced binding sites (LIBS) on GP IIb/IIIa receptors,
hich become exposed only upon activation by receptor-ligand
inding, has been developed [81–83] The LIBS antibody has been
hown to bind only to activated platelets, e.g. when adherent
o damaged endothelium, and does not to bind to non-activated
irculating platelets. von zur Muhlen et al. recently applied cobalt-
unctionalized MPIO (1m diameter) conjugated to the histidine
ag of LIBS single-chain antibodies (LIBS-MPIO) for the detection
f activated platelets in a mouse model of endovascular platelet
ggregation using ex vivo MRI (11.7 T) (Fig. 4A) [43]. LIBS-MPIO
gent have also been applied in a mouse model of wall-adherent,
arotid thrombosis for the detection of platelet-rich thrombi by in
ivo MRI (Fig. 4C) [44]. LIBS-MPIO reliably tracked a reduction in
hrombus size in response to pharmacological thrombolysis treat-
ent with urokinase (Fig. 4D). LIBS-MPIO have also been used
o detect human platelet aggregates in explanted symptomatic
arotid artery plaque specimens by ex vivo MRI (9.4 T) [44] and
uman platelet-rich clots in vitro using clinically relevantmagnetic
eld strengths (3 T) [84].
0. Clinical translation of MPIO
For clinical purposes, the commercial MPIO that we have used
re non-biodegradable, due to their polyurethane coat, and are not
uitable for human applications. However, for clinical translation, it
hould be feasible to synthesize biodegradable MPIO with suitable
odiﬁcationof the surface coat, similar to the ironoxide containing
ontrastmedia that are already in clinical use [85]. In fact, thedevel-
pment of biodegradable MPIO suitable for clinical use is already
nderway [86–89].Our ligand-targetedMPIOapproachhas focused
n the use ofmonoclonal antibodies. Potential immunogenicity can
e attenuated by the use of modiﬁed or “humanized” antibodies
90] and single-chain antibodies [43,82]. However, antibody pro-
uction on a scale required for clinical application is also relatively
omplex and expensive. Sugar-based ligands, such as sLeX, have
ecently beenapplied todevelopnovel glyconanoparticles [91], and
ay prove useful ligands for clinical application.
For our in vivo imaging studies, the dose of iron that we have
sed (4.5mg iron/kg body weight) has been well tolerated, with
o animals showing any short-term ill effects. This iron dose
losely reﬂects the dose ofUSPIO (2.6mg iron/kg bodyweight) used
xtensively for human oncological MRI [92]. Further dose-ranging
tudies will determine whether the iron dose can be reduced fur-
her. Importantly, MPIO, which are considerably smaller than red
lood cells (Fig. 5A), do not induce any evidence of hemorrhage or
issue infarction due to small vessel ‘plugging’ [11] and are rapidly
equestered by the liver and spleen (Fig. 5B) [43]. Another impor-
ant advantage of theMPIO approach is the ability to relate speciﬁc
PIO binding to the blood vessel architecture [10]. The anatomical
[
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distribution together with the degree and timing of contrast bind-
ing may add further functional speciﬁcity for vascular pathological
processes under evaluation.
11. Conclusions
In summary, we have developed a new approach to molec-
ular imaging of endovascular targets using ligand-conjugated
MPIO, which we have applied in a diverse range of vascular syn-
dromes including acute brain inﬂammation, atherosclerosis, renal
ischemia-reperfusion injury, ischemic stroke and thrombus forma-
tion. The versatility of functionalized MPIO and the potency of the
contrast effects in detecting relatively low-abundance endothe-
lial molecular targets, offers a potentially valuable platform for
accelerating diagnosis and guiding speciﬁc treatment of vascular
inﬂammatory diseases.
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